This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
BMC Public Health Open Access 13 April 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Murata, Y. Respiratory syncytial virus infection in adults. Curr. Opin. Pulm. Med. 14, 235–240 (2008).
Wu, H. et al. Immunoprophylaxis of RSV infection: advancing from RSV-IGIV to palivizumab and motavizumab. Curr. Top. Microbiol. Immunol. 317, 103–123 (2008).
Dall'Acqua, W. F. et al. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor. J. Biol. Chem. 281, 23514–23524 (2007).
Fulginiti, V. A. et al. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am. J. Epidemiol. 89, 435–448 (1969).
Schickli, J. H. et al. Challenges in developing a paediatric RSV vaccine. Hum. Vaccin. 5, 582–591 (2009).
Olszewska, W. & Openshaw, P. Emerging drugs for respiratory syncytial virus infection. Expert Opin. Emerg. Drugs 14, 207–217 (2009).
Henderson, E. A. et al. 1,4-benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J. Med. Chem. 50, 1685–1692 (2007).
Bitko, V. et al. Inhibition of respiratory viruses by nasally administered siRNA. Nature Med. 11, 50–55 (2005).
Gill, M. A. & Welliver, R. C. Motavizumab for the prevention of respiratory syncytial virus infection in infants. Expert Opin. Biol. Ther. 9, 1335–1345 (2009).
Resch, B. et al. Cost-effectiveness of palivizumab against respiratory syncytial virus infection in high-risk children in Austria. Clin. Ther. 30, 749–760 (2008).
Ramirez, J. A. RSV infection in the adult population. Manag. Care 17, 13–15 (2008).
Makari, D. et al. Impact of RSV: implications for managed care. Manag. Care 18, 2–7 (2009).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Storey, S. Respiratory syncytial virus market. Nat Rev Drug Discov 9, 15–16 (2010). https://doi.org/10.1038/nrd3075
Issue Date:
DOI: https://doi.org/10.1038/nrd3075
This article is cited by
-
Evolutionary dynamics of group A and B respiratory syncytial virus in China, 2009-2018
Archives of Virology (2021)
-
The present state of the art in expression, production and characterization of monoclonal antibodies
Molecular Diversity (2016)
-
An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children
BMC Public Health (2011)
-
Strategies and challenges for the next generation of therapeutic antibodies
Nature Reviews Immunology (2010)